Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03033511
Title A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie

lung small cell carcinoma


Dexamethasone + Rovalpituzumab Tesirine

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.